文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV-1嗜性基因型检测有助于识别治疗选择耗尽且疾病进展者

Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

研究纳入1382例联合抗逆转录病毒治疗失败的经验治疗患者,通过Geno2Pheno推断HIV-1嗜性,评估累积耐药与药物活性。结果显示30.5%为X4/双混合株,FPR≤5%者耐药程度更高、CD4更低,嗜性检测有助于识别治疗选择有限的高危人群。

要点

  • cART失败者中30.5%存在X4/双混合株,FPR≤5%者占22.2%。
  • FPR≤5%者CD4最低值更低,对PI、NRTI、INI耐药比例更高。
  • 对≤2种活性药物敏感者总体约2%,FPR≤5%者达4.6%。

核心结论

  • cART失败者中小部分治疗选择有限,嗜性检测有助于识别高耐药和疾病进展风险者。

研究设计与样本

  • 对1382例cART失败的经验治疗患者进行基因型嗜性推断和耐药分析。

主要发现

  • 30.5%为X4/双混合株,FPR≤5%者22.2%,FPR5%-10%者8.3%。
  • FPR降低时CD4最低值和末次GRT时CD4显著下降,CD4<200、围产期感染和长治疗史比例增加。
  • 933例(67.5%)至少对一类药物耐药,NRTI、NNRTI、PI、INI耐药分别占52.7%、48.2%、23.5%、13.2%。
  • FPR≤5%者对PI、NRTI、INI耐药水平显著更高,对≤2种活性药物敏感者占4.6%。

关键数值与推荐

  • 嗜性以FPR≤5%定义为X4/双混合株,FPR5%-10%为另一层。
  • 耐药累积和药物活性采用Stanford算法评估。
  • 对≤2种活性药物敏感者总体约2%,FPR≤5%者为4.6%。

临床怎么用

  • 对cART失败且治疗选择有限者,可考虑基因型嗜性检测辅助识别高耐药和进展风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate HIV-1 tropism in 1382 combined antiretroviral therapy (cART)-experienced patients failing therapy to characterize those with exhausted therapeutic options. METHODS: HIV-1 genotypic tropism was inferred through Geno2Pheno by estimating the false-positive-rate (FPR) values. Cumulative resistance and drug activity were evaluated by Stanford algorithm. RESULTS: Overall, median (IQR) CD4 count (cells/mm3) nadir and at last genotypic resistance test (GRT) available were 98 (33-211) and 312 (155-517), respectively. Considering HIV-1 tropism, 30.5% had X4/dual-mixed strains (FPR ≤5%: 22.2%; FPR 5%-10%: 8.3%). By stratifying according to tropism, by decreasing FPR, a significant decrease of CD4 nadir and at last GRT was observed. The proportion of individuals with CD4 count <200 cells/mm3, who were perinatally infected and with a long treatment history significantly increased as FPR levels decreased. Regarding resistance, 933 (67.5%) individuals accumulated at least one class resistance, with 52.7%, 48.2%, 23.5% and 13.2% of individuals showing resistance to NRTIs, NNRTIs, PIs and INIs; while 23.2%, 27.2%, 14.3% and 2.8% harboured resistance to 1, 2, 3 and 4 classes, respectively. Individuals with FPR ≤5% showed a significantly higher level of resistance to PIs, NRTIs and INIs compared with others. The proportion of individuals harbouring strains susceptible to ≤2 active drugs was only about 2%; nonetheless, this proportion doubled (4.6%) in patients infected with FPR ≤5%. CONCLUSIONS: Our findings showed that a small proportion of cART failing individuals have limited therapeutic options. However, tropism determination might help to identify people who have accumulated a high level of resistance and have a greater risk of advanced disease.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Bouba Y, Armenia D, Forbici F, et al. Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. J Antimicrob Chemother. 2021. PMID: 34529797. doi:10.1093/jac/dkab322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。